Biotech Market Research – Different Approach To Stay Ahead Of Your Competitor

FRAGILE X SYNDROME NEWSLETTER Fragile X Syndrome , a syndrome, which results in intellectual disabilities as well as affects the physical characteristics of the people suffering from it, is a result of mutation associated with the gene known as FMR1. As per DelveInsight assessments, the market size of Fragile X Syndrome (FXS) in the 7MM was found to be  USD 33.51 Million in 2017 , for the study period, 2017–2028. Top companies involved fuelling the FXS Market are: Tetra Therapeutics, Zynerba Pharmaceuticals, Ovid Therapeutics, Confluence Pharmaceuticals, Neuren Pharmaceuticals, and others. Through its Newsletter series, DelveInsight aims to brings to light an overview of Fragile X syndrome, along with its epidemiological scenario, treatment landscape and upcoming therapies in the pipeline that shall drive the market forward. Visit to gain access to our Newsletter:  https://www.delveinsight.com/whitepaper-newsletter/fragile-x-syndrome

(Albany, US)  DelveInsight has launched a new report on Genital Warts Market Insights, Epidemiology and Market Forecast-2030 . DelveInsight’s  ‘ Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast-2030  report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GWs in the United States.   Add caption Some of the key facts of the Report: HPV 6 and 11 cause greater than 90% of genital warts cases in males and females. Approximately 3–4 million cases of genital warts in men occur each year with a peak rate of 500 per 100,000 in the 25–29 year old group. The incidence rate of GWs among all men in the study was 2.35 cases per 1000 person-years, with the highest incidence of 3.43 cases per 1000 person-years observed among men aged 18–30 years. Key benefits of the Report 1. Genital Warts market report covers a descriptive overview and comprehensive

An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also called Glycogen Storage disease type II, Pompe disease affects around 5,000 to 10,000 people worldwide, with an equal preponderance in Males and females. DelveInsight's newsletter series brings to light an overview of Pompe disease, underlying cause, Etiology, Symptoms, Market and Epidemiology. Top companies involved : Tetra Therapeutics , Zynerba Pharmaceuticals , Ovid Therapeutics , Confluence Pharmaceuticals, and Neuren Pharmaceuticals. Have a Copy our Newsletter : https://www.delveinsight.com/whitepaper-newsletter/pompe-disease hashtag

The growth of Duchenne Muscular Dystrophy (DMD)  Market is anticipated to increase because of an increasing incidence of DMD patients as well as the launch of emerging drugs in the 7MM. DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on " Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030 " to its portfolio. Key Highlights from the report are: As per the DelveInsight analysis, the total diagnosed Duchenne Muscular Dystrophy prevalent population in the 7 MM was 27,685 in 2017. The total diagnosed prevalent cases of DMD patients were found to be maximum in the age-group of 8–13 year and 14–19 year in  the United States  in 2017. The treatment for DMD patients is the standard care along with the new upcoming therapeutic strategies covering Genetic Therapies, Cell therapy using muscle precursor cells or stem cells, Membrane stabilization and upregulation of cytoskeletal proteins and secondary ca

DelveInsight’s ‘ Immune Thrombocytopenia (ITP)  Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. Some Key facts of the Report Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States. DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017. The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017. In 2017, there were around 63,725 prevalent cases and approximately 53,362 diagnosed prevalent cases of ITP in the United States. Out of the total diagnosed cases, approximately 49,640 cases account for adult ITP

DelveInsight has launched a new report on " Immune thrombocytopenia (ITP) Pipeline Insight, 2020 ". " Immune thrombocytopenia (ITP) Pipeline Insight, 2020 " report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the  Immune thrombocytopenia (ITP)  market. A detailed picture of the  Immune thrombocytopenia (ITP)  pipeline landscape is provided, which includes the disease overview and  Immune thrombocytopenia (ITP)  treatment guidelines. The assessment part of the report embraces in-depth  Immune thrombocytopenia (ITP)  commercial assessment and clinical assessment of the  Immune thrombocytopenia (ITP)  pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,  Imm

DelveInsight has launched a report on “ Interstitial Cystitis Pipeline Insight, 2020 ”. " Interstitial Cystitis Pipeline Insight, 2020 " report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the  Interstitial Cystitis  market. A detailed picture of the  Interstitial Cystitis  pipeline landscape is provided, which includes the disease overview and  Interstitial Cystitis  treatment guidelines. The assessment part of the report embraces in-depth  Interstitial Cystitis  commercial assessment and clinical assessment of the  Interstitial Cystitis  pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,  Interstitial Cystitis  collaborations, licensing, mergers and acquisition,

DelveInsight has launched a report on “ Interstitial Cystitis Epidemiology Forecast to 2030 ”. DelveInsight's ' Interstitial Cystitis Epidemiology Forecast to 2030 ' report delivers an in-depth understanding of the disease, historical and forecasted Interstitial Cystitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the Facts: According to DelveInsight, the total prevalent population of Interstitial Cystitis in the Seven Major Markets was approximately 8,517,779 in 2017. In the epidemiology model, the analystsreported a higher prevalence of Interstitial Cystitis the United States with around 5,000,101 prevalent cases in 2017. Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with 844,367 cases. Spain had the lowest prevalent population of 4,95,983 in 2017. Request for Sample Pages:  https://www.delveinsight.com/sample-request/in